Novo Nordisk's Pipeline Patience Wears Thin as US Headwinds Build
Published on 10/17/2026 at 12:30 | Editorial boerse-global.de
Novo Nordisk shares ended Friday at EUR 34.49, down 1.4%, extending a year-to-date decline of 22% that has left the stock 37% below its 52-week high. The retreat comes as investors weigh a trio of pressures: cooling growth expectations in the GLP-1 franchise, a lengthening regulatory review for a key pipeline asset, and a US market where rivals are gaining ground.
A widely circulated report on preclinical semaglutide research briefly drew attention earlier in the week, but the mouse study — funded by the US NIH and pointing to effects on age-related markers — has no demonstrated equivalent in humans and bore no causal link to the share price move. Market watchers have their eyes fixed elsewhere: on the core operating business and the imminent quarterly results, where the trajectory of the company's blockbuster products will take center stage.
Analysts Trim Their Sights
Citi cut its price target on the Danish drugmaker to DKK 296 from DKK 310 on October 9, keeping a "Neutral" rating. The revision rested on expectations of only limited operating margin expansion through the end of the decade. BMO Capital followed on October 12, lowering its fair value to $40 from $47 while maintaining "Market Perform," citing eroding US market share and a tough year-ago comparison for the diabetes drug Ozempic that is likely to weigh on third-quarter 2026 revenue.
The cautious tone from the sell side lands on a sensitive spot. After years of breakneck expansion, concern is mounting that the GLP-1 segment is normalizing, with pricing pressure and emerging rival products casting doubt on whether Novo can sustain its earlier growth rates. Defending its position in the US — the company's most important market — has become a stiffer task as competition strengthens.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Denecimig Review Stretches On
The development pipeline has its own headaches. The US Food and Drug Administration is continuing its review of the hemophilia A candidate Denecimig without setting a new decision timeline. The agency attributed the delay to required remediation work at a manufacturing site and explicitly noted that no deficiencies were found in clinical efficacy or safety data.
Novo Nordisk said the setback does not affect its financial guidance for 2026. Subject to regulatory approval, the company is targeting a US launch in the first half of 2027. For the group, the postponement means a portfolio expansion beyond its dominant diabetes and obesity franchises will take longer to arrive — leaving the established therapies to carry the load in the near term.
Buyback Keeps Running
Management is leaning on steady capital returns to support the stock. Under a program with a maximum volume of DKK 15 billion running over twelve months, Novo had repurchased B-shares worth DKK 6,447,270,879 through October 2, 2026, the company said on October 5. The buybacks underpin the market but cannot dispel investor reticence in the face of margin and competitive pressure in the US.
Longer-term growth is being sought beyond established markets. Management reportedly expects annual growth of 15% to 20% in India's GLP-1 market, where Novo is preparing a higher-dose version of semaglutide and an oral obesity therapy for a possible launch in mid-2027, pending regulatory clearance.
For now, caution prevails on the trading floor. The combination of sharper competition in the core business and regulatory delays frames the outlook for the months ahead — with the coming quarterly update set to test whether the company can still deliver on the operating front.
Ad
Novo Nordisk Stock: New Analysis - 17 October
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
